Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioSpace characterized the deal as a defensive bolt-on amid Sanofi's eroding Lantus franchise and slowing diabetes growth — 'an attempt to bolster sagging…
Scrip flagged Hanmi's commercial dilemma after Sanofi returned efpeglenatide: positive Phase 3 cardiovascular and renal data could not offset the loss of a…
AMPLITUDE-O at ADA 2021 (n=4,076) showed efpeglenatide cut MACE by 27% and kidney events by 33% versus placebo — strong CV outcomes data that came too late to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi acquired exclusive worldwide rights to Hanmi's three-asset Quantum Project diabetes portfolio (efpeglenatide, weekly insulin, weekly GLP-1/insulin combo) for euro 400M (~$435M) upfront plus up to euro 3.5B (~$3.77B) in milestones plus double-digit royalties. Sanofi returned partial rights December 2016 (insulin and combo product); efpeglenatide rights returned to Hanmi in May 2020.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Hanmi Pharmaceutical Co., Ltd. (Quantum Project) (this deal) | 2015 | $4.2B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2015 deals · Sanofi SA deals · Metabolic deals